On 24 March 2022, “Invest to end TB. Save lives”, the striking slogan lit up on the screen of 28 Liberty in Manhattan, New York City. On that day, the slogan was also featured on many other global landmarks of Fosun, including the Bund Financial Center in Shanghai, YOSUN Wuhan International Fashion Center, Fosun International Center Chongqing, Forte Woli

On 24 March 2022, Fosun International held its 2021 annual results presentation in the form of online webcast. Guo Guangchang, Chairman of Fosun International, Wang Qunbin, Co-Chairman of Fosun International, Chen Qiyu and Xu Xiaoliang, Co-CEOs of Fosun International, Gong Ping, Executive President and Chief Financial Officer of Fosun Intern

2021 Annual Results Summary and Highlights:Total operating revenue for the year amounted to RMB161.29 billion, representing a year-on-year increase of 18%; profit attributable to owners of the parent reached RMB10.09 billion, representing a year-on-year increase of 26%;Profit of industrial operations amounted to RMB10.59 billion, representing a year-on-year increase of 30%;In

Results HighlightsBenefiting from the strong rebound of its businesses in the second half year, the business volume of tourism operations increased by 20% in 2021, with adjusted EBITDA reaching RMB3 million. Both business volume and adjusted EBITDA in the second half year rebounded notably, the business volume of tourism operations rose by 122.1% year-on-year, with adj

Wednesday March 23rd, 2022 Lanvin Group is a global luxury fashion group that owns the oldest operating French couture house Lanvin, Italian luxury shoemaker Sergio Rossi, Austrian skinwear specialist Wolford, iconic American womenswear brand St. John Knits, and high-end Italian menswear maker CarusoStrong foundation in Europe combined with a unique position to ca

Highlights:Revenue for the year ended December 31, 2021 was RMB39,005 million, representing an increase of 28.70% YOY;The proportion of revenue from new products as well as regions outside Mainland China and countries overseas continue to increase, continuously optimizing the revenue structure;In 2021, the revenue from new and sub-new products including CO

SHANGHAI CHINA, March 18, 2022—Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “Group”; Stock Code: 600196.SH, 02196.HK) announced that Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (“‘Fosun Pharmaceutical Industrial”), a subsidiary company of Fosun Pharma, has signed a sublicense agreement with the Medicines P